We offer a genetic cancer screening which is covered by Medicare 100% for those who qualify by doing a very simply non evasive BRCA1 & BRCA2 cheek swab. Our CLIA CERTIFIED laboratory partners employ CGX panels which test for the 39 most relevant gene markers which allow the provider and patient to understand if they are predisposed to acquiring cancer.
Early Detection and 3 generational knowledge of potential Cancer genes. Genetic testing to build a larger database to discover cancer before it is detected.
Our Pharmacogenomic testing is used to reduce the 4th leading cause of death by adverse drug reactions.
We are leaders in the revolution of prevention diagnosis and treatment of diseases by providing the public and healthcare providers with clinically actionable information that promotes patient personalized care.
We are the marketing and distribution channel for our national CLIA certified state of the art automated lab services provided with the latest in Next Generation Sequencing (NGS) technology that allows us to process and decode the entire human genome with the highest standard of quality. We have been in the lab industry for over 20 years, we have become a leading bio science firm and provide the most advance clinical genetic sequencing services to patients, doctors, and hospitals across the entire U.S.
We are the nation's leading provider in revolutionary new lab tests for Hereditary Cancer screening (CGX) which tests for an industry leading 39 relevant genetic markers. This allows the patient to understand if they are predisposed to acquiring cancer. By analyzing a person's DNA we are able to search for specific genetic variants that put one at an increased risk of Hereditary Cancer. By using the latest advances in Next Generation Sequencing (NGS) this allows us to analyze a patient's sample and this provides us comprehensive reports of genetic variants and risk factors. The ordering physician supported by our genetic counselors is able to formulate a treatment protocol to address any negative findings including suggesting a follow up with the patient's local physician to have additional testing. Awareness of one's risk factors allows patients and their physicians to take a proactive rather reactive approach to managing identified risks.
We also provide pharmacogenomics (PGX) tests which is a type of genetic test to predict a patient's likelihood to experience an adverse event or not respond to a given pharmaceutical drug especially heart medication, pain medications , or psychitiaric drugs.
We are only looking for HIPAA certified agents to join our team as an independent agent. Email us at firstname.lastname@example.org
If you are a senior center, church, physician, or private practice, please have your representative contact me for an appointment, Don Prentice.
We have designed our next generation sequencing lab from the ground up, with the goal of providing top quality, scalable services in a highly controlled environment. We utilize the latest technologies in order to maintain our position at the cutting edge of next generation sequencing. Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. Using NGS, an entire human genome can be sequenced within a single day.
There are a number of different NGS platforms that use different sequencing technologies; a detailed discussion of which is beyond the scope of this article. However, all NGS platforms perform sequencing of millions of small fragments of DNA in parallel. Bioinformatics analyses are used to piece together these fragments by mapping the individual reads to the human reference genome. Each of the three billion bases in the human genome is sequenced multiple times, providing high depth to deliver accurate data and an insight into unexpected DNA variation . NGS can be used to sequence entire genomes or constrained to specific areas of interest, including all 22,000 coding genes (a whole exome) or small numbers of individual genes.
The fundamental premise of cancer genomics is that cancer is caused by somatically acquired mutations, and consequently it is a disease of the genome. Although capillary-based cancer sequencing has been ongoing for over a decade, these investigations were limited to relatively few samples and small numbers of candidate genes. With the advent of NGS, cancer genomes can now be systemically studied in their entirety, an endeavor ongoing via several large scale cancer genome projects around the world, including a dedicated pediatric cancer genome project. For the child suffering from cancer, this may provide many benefits including a more precise diagnosis and classification of the disease, more accurate prognosis, and potentially the identification of ‘drug-able’ causal mutations. Individual cancer sequencing may, therefore, provide the basis of personalized cancer management. Currently pilot projects are underway using NGS of cancer genomes in clinical practice, mainly aiming to identify mutations in tumors that can be targeted by mutation-specific drugs.